Last reviewed · How we verify
ABI injection — Competitive Intelligence Brief
phase 3
Cardiac ablation agent
Cardiovascular
Biologic
Live · refreshed every 30 min
Target snapshot
ABI injection (ABI injection) — Istanbul Training and Research Hospital. ABI injection is used to treat atrial fibrillation by ablating the heart tissue causing the arrhythmia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ABI injection TARGET | ABI injection | Istanbul Training and Research Hospital | phase 3 | Cardiac ablation agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Cardiac ablation agent class)
- Istanbul Training and Research Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ABI injection CI watch — RSS
- ABI injection CI watch — Atom
- ABI injection CI watch — JSON
- ABI injection alone — RSS
- Whole Cardiac ablation agent class — RSS
Cite this brief
Drug Landscape (2026). ABI injection — Competitive Intelligence Brief. https://druglandscape.com/ci/abi-injection. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab